AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32506857
Drug: Jinying capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinying capsules and oral levofloxacin plus oral metronidazole for first 7 days, followed by Jinying capsules with levofloxacin placebo and metronidazole placebo for another 7 days, and then Jinying capsules only for the remaining 14 days.
Trial: 32506857
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received oral levofloxacin and metronidazole with Jinying capsule placebo for the first 14 days, followed by Jinying capsule placebo only for the remaining 14 days.
Trial: 32506857
Drug: Jinying capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinying capsules (experimental group) vs. Jinying capsule placebo (control group) in TCM symptom pattern scores before and after treatment.
Trial: 36299540
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy with Adaptive Virtual Reality Exposure (CBT-ExpVR)
Trial: 36299540
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy with In Vivo Exposure (CBT-Exp)
Trial: 33655943
Drug: Conventional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatments for neglect symptoms (n=12)
Trial: 33079935
Drug: Nutrient bar
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nutrient bar supplementation (2 bars daily for 2 months)
Trial: 34052212
Drug: IV continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV continuous diuretic therapy
Trial: 34052212
Drug: IV intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV intermittent bolus diuretic therapy
Trial: 34052212
Drug: Oral diuretic
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diuretic therapy
Trial: 34518101
Drug: Remifentanil group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil group (group R) with remifentanil infusion
Trial: 35550819
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Warfarin and antiplatelets)
Trial: 35550819
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (in patients with MS)
Trial: 34257570
Drug: Simultaneous Integrated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous Integrated Boost (SIB) delivered using RapidArc technique at doses of 2.4 Gy per fraction during pelvic irradiation with 50.4/1.8 Gy, total dose of 67.2 Gy for limited volume disease; parametric boost therapy added for advanced disease to a total dose of 79.2 Gy.
Trial: 34257570
Drug: Simultaneous cisplatin‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous cisplatin‐based chemotherapy for 5 cycles with a dosage of 40 mg/m2.
Trial: 32424028
Drug: Antimalarial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimalarial treatment
Trial: 35084726
Drug: Nebulized heliox
RxNorm normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized heliox (helium/oxygen‐70: 30) plus albuterol (10 mL/min for 20 minutes, three times)
Trial: 35084726
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (albuterol in combination with oxygen)
Trial: 34693931
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ARV)
Trial: 34412512
Drug: Endovascular thrombectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular thrombectomy with intravenous thrombolysis
Trial: 34303029
Drug: SRP+aPDT (scaling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP+aPDT (scaling and root planing followed by 3 consecutive applications of antimicrobial photodynamic therapy)
Trial: 32251176
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg)
Trial: 35403286
Drug: Probiotic and
RxNorm normalized name: Florastor Advanced Probiotic And Digestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic and Peanut Oral Immunotherapy (PPOIT)
Trial: 35368052
Drug: SLN360 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLN360 30 mg
Trial: 35368052
Drug: SLN360 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLN360 100 mg
Trial: 35368052
Drug: SLN360 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLN360 300 mg
Trial: 35368052
Drug: SLN360 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLN360 600 mg
Trial: 33758008
Drug: P2Y12 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P2Y12 inhibitor monotherapy after 3-month DAPT
Trial: 36251618
Drug: Levoketoconazole (150-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levoketoconazole (150-600 mg BID)
Trial: 32488909
Drug: Bevacizumab in
RxNorm normalized name: bevacizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab in combination with neoadjuvant chemotherapy (FEC100 and taxanes)
Trial: 36419615
Drug: 4D dietary
RxNorm normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4D dietary supplement containing 150 mg of caffeine
Trial: 32128957
Drug: Efpeglenatide 8
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efpeglenatide 8 mg once monthly
Trial: 32128957
Drug: Efpeglenatide 12
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efpeglenatide 12 mg once monthly
Trial: 32128957
Drug: Efpeglenatide 16
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efpeglenatide 16 mg once monthly
Trial: 32886918
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (external ventricular drain with antibiotics)
Trial: 32991606
Drug: Pelubiprofen CR
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pelubiprofen CR 90 mg
Trial: 32991606
Drug: Aceclofenac 200
RxNorm normalized name: Aceclofenac 200 mg prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac 200 mg
Trial: 32115753
Drug: RAI oral/dental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAI oral/dental items assessment
Trial: 35961692
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel (AC)
Trial: 35961692
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and ticagrelor (AT)
Trial: 35961692
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and prasugrel (AP)
Trial: 34479632
Drug: Emotion-focused mindfulness
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotion-focused mindfulness therapy (EFMT) delivered via telehealth (Zoom)
Trial: 34479632
Drug: Wait list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait list control (no treatment)
Trial: 35711820
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg intramuscular nandrolone
Trial: 34613339
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment (fluoropyrimidine-based chemotherapy with bevacizumab)
Trial: 34613339
Drug: Primary tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary tumor resection (PTR) followed by systemic treatment (fluoropyrimidine-based chemotherapy with bevacizumab)
Trial: 36188617
Drug: Tailin formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailin formulation (TLF) + Continuous low-dose antibiotic therapy (CLAT)
Trial: 36188617
Drug: Continuous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous low-dose antibiotic therapy (CLAT)
Trial: 32936838
Drug: Human monoclonal
RxNorm normalized name: ANTI-A33 FULLY-HUMAN MONOCLONAL ANTIBODY
DrugBank: KRN-330 (DB19075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human monoclonal antibodies (MAbs) derived from genotype B5 virus-infected individuals
Trial: 32936838
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies targeting VP1 S241, VP3 E81, and VP2 D84 on genotype C1 viral capsid
Trial: 32936838
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies in hSCARB2-transgenic mice model
Trial: 35242191
Drug: L‐PRF over
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐PRF over ATBG around immediately inserted implants (test group)
Trial: 35242191
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without L‐PRF)
Trial: 33568038
Drug: Kinesitherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesitherapy combined with daily administration of Fortigel®, Vitamin C, sodium hyaluronate, manganese and copper (Group B)
Trial: 34101206
Drug: Topical silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical silymarin cream 1.4% (3-month treatment)
Trial: 32778175
Drug: D-ribose supplementation
RxNorm normalized name: beta-D-ribose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-ribose supplementation (15g in 200ml solution)
Trial: 34254731
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi intervention (1-hour class twice weekly for 16 weeks)
Trial: 33432459
Drug: Salacia chinensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salacia chinensis (SC; 500 mg)
Trial: 33040778
Drug: Dengzhanshengmai capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengzhanshengmai capsules combined with butylphthalide softgels
Trial: 33040778
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group A (butylphthalide soft capsules)
Trial: 33040778
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group B (Dengzhanshengmai capsules)
Trial: 35435091
Drug: Plasma Exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma Exchange (PE) treatment
Trial: 35900386
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TXA) 500 mg/5 ml
Trial: 35900386
Drug: Moffett’s solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moffett’s solution (control)
Trial: 35217236
Drug: Sitagliptin/metformin (sitaformin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin/metformin (sitaformin)
Trial: 33091433
Drug: SYN023 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYN023 (0.3 mg/kg) alone
Trial: 33091433
Drug: SYN023 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYN023 (0.3 mg/kg) in combination with rabies vaccine
Trial: 38834432
Drug: SYN023 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYN023 (0.3 mg/kg)
Trial: 34419285
Drug: Tivozanib 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib 1.5 mg orally once daily for 21 days in a 28-day cycle
Trial: 32213454
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral psychotherapy (individual and group therapy), mean duration: 64.5 days
Trial: 34706654
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy and conventional physical therapy
Trial: 33485813
Drug: Office Visits
RxNorm normalized name: Office First Aid Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office Visits (OVs) where patients brought their medications into the office for review
Trial: 34384000
Drug: Dutasteride-Tamsulosin 0.5
RxNorm normalized name: dutasteride-tamsulosin 0.5 mg-0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride-Tamsulosin 0.5 mg/0.4 mg capsule formulation (Dakart®)
Trial: 34384000
Drug: Combodart® (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combodart® (reference drug)
Trial: 34710658
Drug: DPCP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPCP with multi‐concentration patch test
Trial: 34710658
Drug: Standard protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protocol for immunotherapy
Trial: 35279970
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.25% ropivacaine with 0.5 μg/kg (1 mL) dexmedetomidine (Group B)
Trial: 35279970
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.25% ropivacaine with 1 mL of normal saline (Group A)
Trial: 32485893
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day biolactis powder (BLP)
Trial: 33352723
Drug: Olaparib (PARPi)
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib (PARPi) + ATR inhibitor AZD6738
Trial: 33352723
Drug: Olaparib (PARPi)
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib (PARPi) + CHK1 inhibitor MK8776
Trial: 33352723
Drug: Olaparib (PARPi)
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib (PARPi) + ATR inhibitor AZD6738 + CHK1 inhibitor MK8776
Trial: 36052331
Drug: 3-month cycle
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month cycle of weekly virtual museum tours of the Montreal Museum of Fine Arts (MMFA)
Trial: 35997601
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy and education
Trial: 33193807
Drug: Convolutional Neural
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Convolutional Neural Network (CNN) with cheat sheet and data augmentation
Trial: 33984876
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of lavender aroma
Trial: 33984876
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of spring orange aroma
Trial: 33638954
Drug: EMDR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMDR therapy (4 sessions, 60 minutes each) plus standard treatment
Trial: 32847923
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol (10 mg)
Trial: 32847923
Drug: Insulin/glucose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin/glucose intravenous infusion (10 units of short-acting insulin in an intravenous bolus with 500 mL of 10% glucose)
Trial: 32847923
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nebulised salbutamol and insulin/glucose intravenous infusion (10 units of short-acting insulin in an intravenous bolus with 500 mL of 10% glucose combined with 10 mg of nebulised salbutamol)
Trial: 33836990
Drug: Intravitreal conbercept
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal conbercept (IVC) 0.25 mg/0.025 mL
Trial: 33045627
Drug: Percutaneous pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous pulsed radiofrequency treatment of the dorsal root ganglia
Trial: 33045627
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no radiofrequency treatment)
Trial: 32827209
Drug: Bupivacaine combined
RxNorm normalized name: bupivacaine, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine combined with ketorolac 15 mg/side for TAP block (TK group)
Trial: 32827209
Drug: Bupivacaine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine for TAP block and 30 mg postoperative intravenous ketorolac (T group)
Trial: 32827209
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg postoperative intravenous ketorolac alone (C group)
Trial: 32164142
Drug: Post-marketing vaccines
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-marketing vaccines (specific types mentioned: influenza, rotavirus, cholera, pneumonia, EV71)
Trial: 38198456
Drug: MDMA-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA-assisted therapy
Trial: 32223100
Drug: Sildenafil regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil regular (50 mg qd)
Trial: 32223100
Drug: Sildenafil on-demand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil on-demand (100 mg 30 minutes before intercourse)
Trial: 32223100
Drug: Tadalafil regular
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil regular (10 mg qd)
Trial: 34920291
Drug: Gatipotuzumab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatipotuzumab (500 mg followed by 1700 mg 1 week later) every 3 weeks until tumor progression or unacceptable toxicity
Trial: 36396522
Drug: Colchicine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 1.5 mg/day
Trial: 36240638
Drug: Probiotics (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (1 g/kg and 2 g/kg)
Trial: 36240638
Drug: Diet acidifier
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet acidifier (2 g/kg and 3 g/kg)
Trial: 36240638
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of probiotics and acidifier
Trial: 34156097
Drug: Topical epinephrine
RxNorm normalized name: epinephrine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical epinephrine 1:1,000
Trial: 34156097
Drug: Topical epinephrine
RxNorm normalized name: epinephrine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical epinephrine 1:10,000
Trial: 35593928
Drug: Collagen membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen membrane group (CM) - collagen membrane coverage after rotary instrument preparation
Trial: 33093297
Drug: Informational video
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Informational video for patients regarding antibiotics in diverticulitis
Trial: 33093297
Drug: Evidence summaries
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence summaries for physicians regarding antibiotics in diverticulitis
Trial: 33093297
Drug: Non-antibiotic strategy
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-antibiotic strategy
Trial: 35126605
Drug: Yushen Tongluo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yushen Tongluo Granule (YSTLG) combined with Clomiphene Citrate (CC)
Trial: 33184166
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injectate (3 x 10 mL aliquots)
Trial: 33184166
Drug: Sham injectates
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injectates (3 x 10 mL)
Trial: 35121091
Drug: Nefopam (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (80 mg continuous intravenous infusion for 24 hours)
Trial: 35598597
Drug: Tanshinone IIA
RxNorm normalized name: autoprothrombin IIA
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanshinone IIA (TSA) at concentrations of 1 μg/mL, 10 μg/mL, 100 μg/mL, and 1 mg/mL plus 5 U/mL of thrombin
Trial: 35598597
Drug: 5 U/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 U/mL of thrombin
Trial: 36354237
Drug: PureRegen Gel
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PureRegen Gel (PRG)